Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.

Saved in:
Bibliographic Details
Title: Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.
Authors: Yu K; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tidwell RS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bathala TK; Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sheth RA; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Karki M; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chen J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas., Qian J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas., Duan F; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas., Perelli L; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Soeung M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rao P; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Siefker-Radtke AO; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Daw NC; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ingram DR; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shamsutdinova D; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wani KM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang WL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lazar AJ; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhao Z; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Prabhakaran S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bota-Rabassedas N; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yang L; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas., Lin C; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas., Genovese G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, Texas., Gao J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas.; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tannir NM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Msaouel P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas.
Corporate Authors: Rare Tumor Initiative Team, Patient Mosaic Team
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 May 15; Vol. 32 (10), pp. 1946-1961.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-25-4518